Skip to main content
. 2019 Mar 8;98(5):1071–1082. doi: 10.1007/s00277-019-03625-x

Fig. 1.

Fig. 1

Treatment algorithm for prevention of thromboembolic events in PV. HCT, hematocrit; VKA, vitamin K antagonists